Authorized purpose: Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.
Clinical role
Image post-processing, registered multiparametric-MRI visualization, semi-automatic prostate segmentation, volume computation, manual editing, ROI analysis, and structured PI-RADS review to assist interpretation.
Images and patients
MRI · Prostate
Key limitation
Keep in mind: Diagnosis should not be made solely from the analysis. Trained users must review the registered images, segmentations, measurements, overlays, and PI-RADS workflow output, and edit the semi-automatic segmentation when needed. The exact cleared population is prostate MR studies; performance outside the labeled anatomy, sequences, data quality, and local workflow is unknown.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Prostate Input: DICOM-compatible prostate MRI data including T2-weighted, diffusion-weighted, ADC, and dynamic-contrast-enhanced sequences.
Who uses it?Intended users: Trained medical professionals.
What does the software produce?Output: Registered and optionally combined MRI views, image overlays, editable segmentations, prostate and ROI volumes, PSA-density calculations, average ADC values, PI-RADS scores, ROI locations, and review information for trained-user interpretation.
What is its most important limitation?Key limitation: Diagnosis should not be made solely from the analysis. Trained users must review the registered images, segmentations, measurements, overlays, and PI-RADS workflow output, and edit the semi-automatic segmentation when needed. The exact cleared population is prostate MR studies; performance outside the labeled anatomy, sequences, data quality, and local workflow is unknown.
Clinical takeaway. Clinical role: Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation in which all system requirements met pre-defined acceptance criteria, bench testing that characterized the stand-alone performance of the prostate segmentation algorithm, and clinical performance testing of the semi-automatic segmentation algorithm comparing clinicians segmenting the prostate with and without Quantib Prostate. It concludes a trained medical professional using Quantib Prostate performs better or equal in prostate segmentation than without it. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Quantib Prostate is image post-processing software for processing, visualizing, and editing prostate MRI images. It supports registered multiparametric-MRI viewing, optional combined-image visualization, semi-automatic anatomical segmentation, volume computation, manual editing, and a structured PI-RADS workflow to assist trained medical professionals interpreting prostate MR studies; diagnosis should not be made solely from its analysis.
Registered and optionally combined MRI views, image overlays, editable segmentations, prostate and ROI volumes, PSA-density calculations, average ADC values, PI-RADS scores, ROI locations, and review information for trained-user interpretation.
Clinical prostate MRI interpretation and post-processing workflows.
Exact FDA submission
Checked 2026-09-04
The FDA indication describes use in a clinical setting; inpatient, outpatient, screening, and service-line deployment boundaries require local confirmation.
Diagnosis should not be made solely from the analysis. Trained users must review the registered images, segmentations, measurements, overlays, and PI-RADS workflow output, and edit the semi-automatic segmentation when needed. The exact cleared population is prostate MR studies; performance outside the labeled anatomy, sequences, data quality, and local workflow is unknown.
The exact FDA document reports software verification and validation in which all system requirements met pre-defined acceptance criteria, bench testing that characterized the stand-alone performance of the prostate segmentation algorithm, and clinical performance testing of the semi-automatic segmentation algorithm comparing clinicians segmenting the prostate with and without Quantib Prostate. It concludes a trained medical professional using Quantib Prostate performs better or equal in prostate segmentation than without it. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The testing results support that all the system requirements have met their pre-defined acceptance criteria." … "Bench testing was done to show that the system is suitable for its intended use and to characterize the stand-alone performance of the prostate segmentation algorithm.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation in which all system requirements met pre-defined acceptance criteria, bench testing that characterized the stand-alone performance of the prostate segmentation algorithm, and clinical performance testing of the semi-automatic segmentation algorithm comparing clinicians segmenting the prostate with and without Quantib Prostate. It concludes a trained medical professional using Quantib Prostate performs better or equal in prostate segmentation than without it. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The testing results support that all the system requirements have met their pre-defined acceptance criteria." … "Bench testing was done to show that the system is suitable for its intended use and to characterize the stand-alone performance of the prostate segmentation algorithm.". Read from the exact FDA decision document on 2026-11-14.
No exact-submission sensitivity endpoint with a verified threshold, population, tested version, and source was identified or promoted.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
No exact-submission specificity endpoint with a verified threshold, population, tested version, and source was identified or promoted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K202501 FDA evidence package for Quantib Prostate
DesignFDA 510(k) decision evidence package with software verification and validation and clinical-use evaluation of semi-automatic prostate segmentation after trained-user correction.
PopulationProstate multiparametric MRI studies within the K202501 labeled workflow.
Scopeexact submission
Tested versionQuantib Prostate configuration described in K202501
IndependenceSponsor or vendor study
K202501
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and it does not establish autonomous diagnosis or patient outcomes.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K202501 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable prostate MRI and radiology service line and verify payer, site-of-service, coding, and coverage assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compatible prostate MRI data including T2-weighted, diffusion-weighted, ADC, and dynamic-contrast-enhanced sequences.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA material describes DICOM-compatible prostate MRI data and a PACS/image-post-processing workflow. Confirm interface versions, patient identity, sequence mapping, PACS/RIS/EHR compatibility, routing, storage, report behavior, and downtime handling locally.
Scope: Exact FDA submission. FDA-described DICOM compatibility does not prove compatibility with a specific local PACS, RIS, EHR, or orchestrator.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The prior exact-submission review identifies an on-premise deployment category for the Quantib AI Node extension on off-the-shelf hardware. Confirm the current hosting region, data flow, system sizing, commercial configuration, and service boundary with the vendor.
Scope: Exact FDA submission. The deployment category is preserved from the prior exact-submission review; current commercial architecture requires confirmation.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Registered and optionally combined MRI views, image overlays, editable segmentations, prostate and ROI volumes, PSA-density calculations, average ADC values, PI-RADS scores, ROI locations, and review information for trained-user interpretation.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Registered and optionally combined MRI views, image overlays, editable segmentations, prostate and ROI volumes, PSA-density calculations, average ADC values, PI-RADS scores, ROI locations, and review information for trained-user interpretation.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The prior exact-submission review identifies an on-premise deployment category for the Quantib AI Node extension on off-the-shelf hardware. Confirm the current hosting region, data flow, system sizing, commercial configuration, and service boundary with the vendor.
Exact FDA submission
Checked 2026-09-04
The deployment category is preserved from the prior exact-submission review; current commercial architecture requires confirmation.
The exact FDA material describes DICOM-compatible prostate MRI data and a PACS/image-post-processing workflow. Confirm interface versions, patient identity, sequence mapping, PACS/RIS/EHR compatibility, routing, storage, report behavior, and downtime handling locally.
Exact FDA submission
Checked 2026-09-04
FDA-described DICOM compatibility does not prove compatibility with a specific local PACS, RIS, EHR, or orchestrator.
Trained medical professionals are the labeled users. Vendor training, onboarding, competency assessment, and support commitments remain commercial implementation details to confirm.
Map the installed Quantib Prostate release, MRI sequences, anatomy, segmentation, measurements, PI-RADS workflow, and enabled functions to K202501 before acceptance.
exact submission · checked 2026-09-04
Later Quantib product-family features are not evidence that this cleared release includes them.
The prior exact-submission review identifies an on-premise deployment category for the Quantib AI Node extension on off-the-shelf hardware. Confirm the current hosting region, data flow, system sizing, commercial configuration, and service boundary with the vendor.
exact submission · checked 2026-09-04
The prior deployment category does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact FDA material describes DICOM-compatible prostate MRI data and a PACS/image-post-processing workflow. Confirm interface versions, patient identity, sequence mapping, PACS/RIS/EHR compatibility, routing, storage, report behavior, and downtime handling locally.
exact submission · checked 2026-09-04
Test representative identifiers, sequence mapping, orientation, overlays, measurements, routing, failure handling, and round trips locally.
Use a signed local test set for the labeled prostate MR workflow. Include common and difficult studies, sequence variation, low-quality or incomplete inputs, segmentation edits, ROI and PI-RADS overrides, and downstream reporting effects. Diagnosis should not be made solely from the analysis. Trained users must review the registered images, segmentations, measurements, overlays, and PI-RADS workflow output, and edit the semi-automatic segmentation when needed. The exact cleared population is prostate MR studies; performance outside the labeled anatomy, sequences, data quality, and local workflow is unknown.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model license and recurring cost against net radiologist and technologist time after review, throughput, repeat work, reporting, infrastructure, interfaces, training, support, downtime, upgrades, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in reviewed public material; productivity or value claims require local evidence.
Track exact software version, MRI sequence and quality, segmentation edits, ROI and PI-RADS overrides, failed studies, repeat work, routing failures, incidents, recalls, updates, and local diagnostic workflow impact.
exact submission · checked 2026-09-04
Revalidate after material software, model, interface, protocol, or clinical-policy changes. Exact-identifier recall review does not exclude family-level signals.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
4Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
Four PubMed records and one trial record were screened. Two PubMed titles name Quantib Prostate, but none identifies the tested software version or links it to K202501; the remaining records are generic. No exact-product/version evidence was promoted, and all five candidates remain quarantined. The current discovery snapshot contains 4 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-04 - Exact FDA submission
FDA materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, interfaces, infrastructure, and included support from the vendor.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-04 - Exact FDA submission
FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, encryption, vulnerability management, backup, and incident-response evidence.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
The exact public materials do not establish a complete live monitoring protocol. Track exact software version, MRI sequence and quality, segmentation edits, ROI and PI-RADS overrides, failed studies, repeat work, routing failures, incidents, updates, and local diagnostic workflow impact.
Authorized purpose: Assist trained radiologists and urologists in reviewing and analyzing prostate MR studies through semi-automatic prostate outlining, multiparametric visualization, and related measurements and reporting; patient-management decisions must not rely on the software alone.
Authorized purpose: Adjunctive review of MR prostate images and biopsy findings for prostate segmentation, lesion evaluation, quantification, documentation, and pre-planning biopsy or soft-tissue-ablation procedures.
Authorized purpose: PROView is an aiding tool for the clinicians to review multi-parametric prostate MR images following PI-RADS guidelines. It displays acquired and reformatted data for visualization and provides tools for assessment of the prostate gland volume and findings analysis in patients with known or suspected prostate lesions. Measurements and associated scoring are included in a report for communication to referring physicians.
Authorized purpose: RSI-MRI+ is indicated for use as automatic post-acquisition image processing software for analysis of diffusion-weighted and anatomical magnetic resonance imaging data. RSI-MRI+ is intended for automatic fusion of derived diffusion-weighted MRI data with anatomical T2-weighted MR images. RSI-MRI+ is additionally intended to provide automatic prostate segmentation, quantification, and reporting of derived image metrics.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.